Gilead Acquires CymaBay: Liver Cure Leap?by Mark Eisenberg 12.02.2024Gilead Sciences acquires CymaBay Therapeutics for $4.3 billion to expand its liver disease portfolio, including access to potential treatment for ...
Piper Sandler Bullish on Tango Therapeutics’ Futureby Mark Eisenberg 12.02.2024Tango Therapeutics receives positive coverage from Piper Sandler, emphasizing its strong position in precision oncology. The firm believes the company's ...
Saudi Market Hits Record High: Pharma Leads, Oil Slipsby Terry Bingman 12.02.2024The Saudi Arabia stock market hits a new 52-week high as pharmaceutical and telecom stocks surge, attracting investor attention.
Bank of America Analysts: Small-Caps the Market’s Hidden Gemby Mark Eisenberg 12.02.2024Despite the market rally, small-cap stocks have become cheaper, making them an attractive option for investors. Bank of America analysts ...
enCore Energy Corp.: $20M Debt Cleared for Growthby Mark Eisenberg 12.02.2024enCore Energy Corp. has eliminated its debt by converting a promissory note into common shares, becoming debt-free and positioning itself ...
Lyft Q4 Update: Key to Future Successby Mark Eisenberg 12.02.2024Financial firm Bernstein believes that Lyft's upcoming fourth quarter update will be key to its future success. The report suggests ...
Bristol Myers Bags RayzeBio in $4.1B Cancer Fight Pactby Mark Eisenberg 12.02.2024Pharma giant Bristol Myers Squibb acquires RayzeBio for $4.1 billion, expanding its presence in the oncology sector and strengthening its ...
Apple’s AI-Driven iPhone Boost Spurs Stock Growthby Lilu Anderson 12.02.2024Analysts predict AI-integrated iPhones could boost Apple's stock and sales, potentially leading to more device replacements and revenue opportunities.
Maximizing Employee Stock Options: Insider Strategiesby Mark Eisenberg 12.02.2024Learn how to maximize the value of your employee stock options (ESOs) with strategies, tips, and long-term planning. A comprehensive ...
Atossa Genetics: Potential Breakthrough in Breast Cancer?by Lilu Anderson 12.02.2024Biopharmaceutical company Atossa Genetics receives Buy rating from H.C. Wainwright, with a new price target of $4.00. The company's promising ...